Related Experiment Videos
Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma
1Division of Haematology and Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|April 13, 2004
Summary
Non-myeloablative allogeneic stem cell transplantation is effective for multiple myeloma in Chinese patients, showing low toxicity and treatment-related mortality. Further studies with longer follow-up are needed to confirm these promising findings.
Area of Science:
- Hematology
- Oncology
- Transplantation Immunology
Background:
- Multiple myeloma is a hematologic malignancy.
- Allogeneic stem cell transplantation is a potential treatment option.
- Non-myeloablative conditioning regimens aim to reduce toxicity.
Purpose of the Study:
- To evaluate the outcomes of non-myeloablative allogeneic stem cell transplantation (NMA-ASCT) in Chinese patients with multiple myeloma.
- To assess the safety and efficacy of NMA-ASCT in this population.
Main Methods:
- Retrospective study of 10 patients with multiple myeloma.
- Patients received fludarabine and total body irradiation as conditioning.
- Non-myeloablative allogeneic stem cell transplantation was performed.
Main Results:
- Successful engraftment was achieved without early treatment-related mortality.
- High rates of donor chimerism were observed.
- Complete or partial remission was achieved in 70% of patients, with all patients alive at 1-year follow-up.
Conclusions:
- Non-myeloablative allogeneic stem cell transplantation is an effective treatment for multiple myeloma.
- The procedure demonstrates low toxicity and treatment-related mortality.
- Further research with larger cohorts and longer follow-up is warranted.